Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30–65 years
- 78 Downloads
To evaluate the adoption of HPV testing and recommended extended cervical cancer screening intervals in clinical practice, we described yearly uptake of Pap/HPV cotesting and estimated length of time between normal screens by patient characteristics.
We examined 55,575 Pap/HPV records from 27,035 women aged 30–65 years from the Johns Hopkins Hospital Pathology Data System between 2006 and 2013. Cotest uptake and median times to next screening test for cotests and cytology only were calculated. Adjusted hazard ratios were estimated using Cox proportional hazards models, with random effects adjustment for clustering within clinic.
Cotest usage increased from < 10% in 2006 to 78% in 2013. The median time to next screening test following normal cytology alone remained constant around 1.5 years. Screening intervals following a dual-negative cotest increased from 1.5 years in 2006/2007 to 2.5 years in 2010, coincident with increases in the proportion of women cotested. Intervals following a dual negative cotest were longer among Medicare patients (3 years) compared with privately insured women (2.5 years), and shorter among black (2 years) compared with white women (2.8 years).
By mid-2013 we observed broad adoption of Pap/HPV cotesting in routine screening in a large academic medical center. Increased screening intervals were observed only among cotested women, while those screened by cytology alone continued to be screened almost annually. The influence of different combinations of race and insurance on screening intervals should be further evaluated to ensure balance of screening risks and benefits in the U.S. population.
KeywordsCervical cancer screening Cytology HPV cotest Screening guidelines Screening interval Implementation Dissemination
- 1.Howlader NNA, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA: SEER Cancer Statistics Review, (1975–2011), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014. 2014
- 2.CDC (2012) behavioral risk factor surveillane system survey data. In. Edited by Services DoHaH. Atlanta: Centers for Disease Control and PreventionGoogle Scholar
- 6.Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FAR, Moriarty AT, Waxman AG, Wilbur DC et al (2012) American cancer society, american society for colposcopy and cervical pathology, and american society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 137(4):516–542CrossRefPubMedGoogle Scholar
- 8.ACOG: Practice Bulletin No. 131 (2012) Screening for cervical cancer. Obstetrics Gynecol 120(5):1222–1238Google Scholar
- 9.Proctor E, Brownson R (2012) Chap. 13: Measurement issues in dissemination and implementation research. Dissemination and implementation research in health: translating science to practice. edn. Edited by Brownson R, Colditz G, Proctor E. New YorkGoogle Scholar
- 10.Zhao C, Li Z, Nayar R, Levi AW, Winkler BA, Moriarty AT, Barkan GA, Rao J, Miller F, Fan F et al (2014) Prior high-risk human papillomavirus testing and papanicolaou test Results of 70 invasive cervical carcinomas Diagnosed in 2012: Results of a Retrospective Multicenter Study. Arch Pathol Lab Med 139:184–188Google Scholar
- 12.Cuzick J, Myers O, Hunt WC, Saslow D, Castle PE, Kinney W, Waxman A, Robertson M, Wheeler CM, on behalf of the New Mexico HPVPRSC, (2014) Human papillomavirus testing 2007–2012: co-testing and triage utilization and impact on subsequent clinical management. Int J Cancer 136:2854–2863Google Scholar
- 15.ACOG (2003) ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45., August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol 102(2):417–427Google Scholar
- 16.Wright TCJ, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, Hatch K, Noller KL, Roach N, Runowicz C et al (2004) Interim guidance for the use of human papillomavirus DNA testing as an adjunct to Cervical cytology for screening. Obstetrics Gynecol 103(2):304–309. https://doi.org/10.1097/1001.AOG.0000109426.0000182624.f0000109428 CrossRefGoogle Scholar
- 19.Rogers E (2003) Diffusion of innovataions, 5th edn. The Free Press, New YorkGoogle Scholar
- 20.Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK (2014) Reassurance Against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst 106(8)Google Scholar
- 21.Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE (2011) Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 12(7):663–672CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Dillner J, Rebolj M, Birembaut P, Petry K-U, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S et al (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337:a1754CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V (2010) Cervical cancer screening with both human papillomavirus and papanicolaou testing vs papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med 170(11):977–986CrossRefPubMedGoogle Scholar
- 32.Yabroff KR, Saraiya M, Meissner HI, Haggstrom DA, Wideroff L, Yuan G, Berkowitz Z, Davis WW, Benard VB, Coughlin SS (2009) Specialty differences in primary care physician reports of papanicolaou test screening practices: a National Survey, 2006 to 2007. Ann Intern Med 151(9):602–611CrossRefPubMedGoogle Scholar
- 34.Berkowitz Z, Saraiya M, Benard V, Yabroff KR (2010) Common abnormal results of pap and human papillomavirus cotesting: what physicians are recommending for management. Obstetrics Gynecol 116(6):1332–1340. https://doi.org/10.1097/AOG.1330b1013e3181fae1334ca CrossRefGoogle Scholar
- 37.FDA approves first human papillomavirus test for primary cervical cancer screening [http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm394773.htm]
- 38.Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FAR, Kinney WK, Massad LS, Mayeaux EJ, Saslow D et al (2015) Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstetr Gynecol. https://doi.org/10.1097/AOG.0000000000000669 Google Scholar
- 39.Chronological History of ACS Recommendations for the Early Detection of Cancer in People Without Cancer Symptoms [http://www.cancer.org/healthy/findcancerearly/cancerscreeningguidelines/chronological-history-of-acs-recommendations]
- 42.USPSTF (1996) Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force. 2nd edn. WIlliams & WIlkins, BaltimoreGoogle Scholar
- 43.USPSTF: U.S. Preventive Services Task Force (2003) Recommendations and rationale-screening for cervical cancer: recommendations and rationale. Am Fam Phys 67(8):1759–1766Google Scholar